Journal for ImmunoTherapy of Cancer (Nov 2021)

235 Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity

Yuji Mishima,
Kanto Nakajima,
Mamoru Shiraishi,
Haruka Matsumura,
Takahiko Aramaki,
Noriko Matsumoto,
Norihiro Nakamura

Affiliations

Yuji Mishima: Brightpath Biotherapeutics, Kawasaki, Japan
Kanto Nakajima: Brightpath Biotherapeutics, Kawasaki, Japan
Mamoru Shiraishi: Brightpath Biotherapeutics, Kawasaki, Japan
Haruka Matsumura: Brightpath Biotherapeutics, Kawasaki, Japan
Takahiko Aramaki: Brightpath Biotherapeutics, Kawasaki, Japan
Noriko Matsumoto: Brightpath Biotherapeutics, Kawasaki, Japan
Norihiro Nakamura: Brightpath Biotherapeutics, Kawasaki, Japan

DOI: https://doi.org/10.1136/jitc-2021-SITC2021.235
Journal volume & issue: Vol. 9, no. Suppl 2

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal